Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

NCT ID: NCT04340986

Last Updated: 2024-06-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-02

Study Completion Date

2030-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The collection of data from patients with CHC and cholangiocarcinomas who are cancers with poor prognosis is a major challenge to improve patients'care (diagnosis, prognosis); facilitate the search for new therapeutic targets and the follow-up of clinical studies; and develop personalized treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholangiocarcinoma Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with Hepatocellular carcinoma

No interventions assigned to this group

patients with Cholangiocarcinoma

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years olds
* Medical care in Nephrology department since 2015

Cholangiocarcinoma:

\- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease

Hepatocellular carcinoma:

* Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI
* Hepatocellular histologically documented

Exclusion Criteria

\- Lack of patient non-opposition
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marie LEQUOY, MD

Role: PRINCIPAL_INVESTIGATOR

AssistancePublique-Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Serviec hépatologie-Hôpital Saint Antoine

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie LEQUOY, MD

Role: CONTACT

+330149283154

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marie LEQUOY, MD

Role: primary

+330149283154

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDRCB 2019-A01679-48

Identifier Type: OTHER

Identifier Source: secondary_id

APHP190473

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Liver Cancer Registry Platform
NCT04510740 RECRUITING